The historic rise of Viagra has long been a benchmark of pharmaceutical success, yet its future within the broader market now raises questions about potential yields . Alternative versions are diminishing patent protection , leading to worries that supporting companies significantly dependent to Viagra's former influence could be a dangerous move ,